With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.
Explore highlights of our research and development pipeline across our five areas of focus.
Items marked with ^ are being developed in collaboration with Regeneron, ❅ are being developed in collaboration with Sangamo Therapeutics, ♕ are being developed in collaboration with Roche, ♢ are being developed in collaboration with SOBI, ✿ are being developed in collaboration with Revolution Medicines, ⚙ are being developed in collaboration with BioNtech, ⚜ are being developed in collaboration with Immunext, ✪ are being developed in collaboration with Denali, ➤ are being developed in collaboration with Lead Pharma and Items shown with a ✜ denote a Phase 1/2 trial. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc. Items shown with ♠ denote opt in rights product for which rights have not been exercised yet. Items shown with ❒ denote identification of out-licensing partner ongoing. Items shown with ♣ denotes Pfizer product.
Product Candidate | Technology | Phase I | Phase II | Phase III | Current Phase |
---|---|---|---|---|---|
Rare Diseases |
|||||
Eliglustat Gaucher disease Type 1, ERT switch Pediatric |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Avalglucosidase alfa Pompe disease |
protein-based therapy | ![]() |
![]() |
![]() |
PHASE III |
Venglustat GM2 Gangliosidosis |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Venglustat Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Adult+Pediatric |
protein-based therapy | ![]() |
![]() |
![]() |
PHASE II |
Venglustat Fabry disease |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
Venglustat Gaucher disease Type 3 |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
SAR339375 Alport Syndrome |
miRNA-21 | ![]() |
![]() |
![]() |
PHASE II |
SAR442501 Achondroplasia |
FGFR3 antibody | ![]() |
PHASE I | ||
Rare Blood Disorders |
|||||
Sutimlimab Cold agglutinin disease |
mAb to C1s | ![]() |
![]() |
![]() |
PHASE III |
Fitusiran Hemophilia A & B |
RNAi | ![]() |
![]() |
![]() |
PHASE III |
Fitusiran Hemophilia A & B - pediatric |
RNAi | ![]() |
![]() |
![]() |
PHASE III |
efanesoctocog alfa (BIVV001)♢ Hemophilia A |
Extended Half Life Factor | ![]() |
![]() |
![]() |
PHASE III |
ST400❅✜ Beta Thalassemia |
ZFN gene editing | ![]() |
![]() |
![]() |
PHASE I/II |
BIVV003❅✜ Sickle Cell Disease |
ZFN gene editing | ![]() |
![]() |
![]() |
PHASE I/II |
Sutimlimab Immune Thrombocytopenic Purpura |
mAb to C1s | ![]() |
![]() |
![]() |
PHASE I |
BIVV020 Cold agglutinin disease |
mAb to C1s | ![]() |
![]() |
![]() |
PHASE I |
Neurology |
|||||
Teriflunomide Relapsing Multiple Sclerosis - Pediatric |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Tolebrutinib Relapsing Multiple Sclerosis (RMS) |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE III |
Tolebrutinib Primary Progressive Multiple Sclerosis (PPMS) |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE III |
Tolebrutinib Secondary Progressive Multiple Sclerosis (SPMS) |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE III |
SAR441344⚜ Multiple Sclerosis |
mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR43820 Amyotropic lateral sclerosis |
RIPK1 inhibitor | ![]() |
PHASE I | ||
Oncology |
|||||
Isatuximab 2L Relapsed Refractory Multiple Myeloma (IKEMA) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Isatuximab 1L Newly Diagnosed Multiple Myeloma Transplant Ineligible (IMROZ) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Isatuximab Newly Diagnosed Multiple Myeloma Transplant Eligible (GMMG) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Isatuximab Smoldering Multiple Myeloma (ITHICA) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ 2L Cervical Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ Adjuvant in Cutaneous Squamous Cell Carcinoma (CSCC) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Tusamitamab ravtansine 2-3L Non-Small Cell Lung Cancer |
ADC | ![]() |
![]() |
![]() |
PHASE III |
Amcenestrant + palbociclib♣ Metastatic Breast Cancer |
small molecule | ![]() |
![]() |
![]() |
PHASE III |
Tusamitamab ravtansine + ramucirumab 2-3L Non-Small Cell Lung Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab + atezolizumab♕ Metastatic Colorectal Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab▼ Patients Awaiting Kidney Transplant |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Isatuximab 1-2L Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) - Pediatrics |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Amcenestrant Early Breast Cancer |
small molecule | ![]() |
![]() |
![]() |
PHASE II |
Amcenestrant 2-3L Metastatic Breast Cancer |
small molecule | ![]() |
![]() |
![]() |
PHASE I |
REGN5458^♠ Relapsed Refractory Multiple Myeloma |
bi-specific mAb | ![]() |
![]() |
![]() |
PHASE I |
REGN4018^♠ Ovarian Cancer |
bi-specific mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR442720✿ Solid Tumors |
small molecule | ![]() |
![]() |
![]() |
PHASE I |
SAR440234 Leukemia |
multi-specific mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR441000⚙ Solid Tumors |
cytokine mRNA | ![]() |
![]() |
![]() |
PHASE I |
SAR439459^ Advanced Solid Tumors |
mAb | ![]() |
![]() |
![]() |
PHASE I |
cemiplimab +REGN4018^♠ Ovarian Cancer |
mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR442085 Multiple Myeloma |
mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR442257 Multiple Myeloma / Non-Hodgkin's Lymphoma |
tri-specific mAb | ![]() |
PHASE I | ||
REGN5459♠ Relapsed Refractory Multiple Myeloma |
bi-specific mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR444245 (THOR-707) Solid Tumors |
non-alpha IL-2 |
![]() |
![]() |
![]() |
PHASE I |
Immunology |
|||||
Dupilumab^ Atopic Dermatitis (6 mo - 5 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Asthma (6-11 years old) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Eosinophilic Esophagitis |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Bullous pemphigoid |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Prurigo nodularis |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Chronic spontaneous urticaria |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Rilzabrutinib Pemphigus |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ COPD |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Cold Urticaria (CindU-Cold) |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Chronic Sinusitis without Nasal Polyps |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Allergic Fungal Rhinosinusitis |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Rilzabrutinib Immune Thrombocytopenia |
BTK inhibitor | ![]() |
![]() |
![]() |
PHASE III |
Itepekimab^ COPD |
mAb | ![]() |
![]() |
![]() |
PHASE III |
Dupilumab^ Grass Pollen Allergy |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Dupilumab^ Peanut Allergy |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Rilzabrutinib IgG4-related disease |
BTK inhibitor | ![]() |
![]() |
PHASE II | |
Sarilumab^ Polyarticular Juvenile Idiopathic Arthritis |
mAb | ![]() |
![]() |
![]() |
PHASE II |
Sarilumab^ Systemic Juvenile Arthritis |
mAb | ![]() |
![]() |
![]() |
PHASE II |
SAR441169➤ Psoriasis |
small molecule | ![]() |
![]() |
![]() |
PHASE I |
SAR441236 HIV |
mAb | ![]() |
![]() |
![]() |
PHASE I |
SAR443122✪ Inflammatory Indications |
RIPK1 inhibitor | ![]() |
![]() |
![]() |
PHASE I |
SAR444727 Immune mediated diseases |
BTK inhibitor | ![]() |
PHASE I |
The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.
As of February 5, 2021.
